Your session is about to expire
← Back to Search
Contingency Management for Cocaine Use Disorder (WRAP Trial)
WRAP Trial Summary
This trial will investigate how changes in brain signaling and cognitive functioning can help people recovering from addiction, as well as using pretreatment neurocognitive functioning to Substance use disorders are prevalent, especially among Veterans, and cocaine addiction in particular has been shown to complicate treatment of other high priority behavioral health problems in the Veteran population. Contingency Management, a behavioral intervention for cocaine users, can be effective, but individual responses are variable and long-term benefits are limited. This trial will test a new model of how CM works by examining brain-based predictors and indicators of treatment response, with the goal of immediate implications for measurement-based implementation of existing CM
WRAP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowWRAP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.WRAP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any severe or unstable health or mental conditions.You are currently pregnant or breastfeeding.I have had a severe brain injury, seizures, or another serious brain condition.My vision is normal, or corrected to normal with glasses or contacts.You must have normal hearing.Only non-military veterans are eligible to participate.You have been diagnosed with a cocaine addiction by a healthcare professional using specific criteria.You are trying to either stop using cocaine completely or reduce the amount of cocaine you use.
- Group 1: Voucher Prize-Based Contingency Management (VoucherPBCM)
- Group 2: Tangible Prize-Based Contingency Management (TangiblePBCM)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being recruited for participation in this experiment?
"Indeed, clinicaltrials.gov indicates that this medical research is currently recruiting patients. The study was first published on November 13th 2019 and the details were last modified on November 14th 2022. It seeks to enrol 180 participants at one specific location."
Am I eligible to join the research project?
"This clinical trial seeks to enroll 180 individuals with cocaine use disorder, aged 18-75. To be eligible for the study, applicants must meet certain criteria including being a Military Veteran and meeting DSM-5 Criteria Cocaine Use Disorder (Mild, Moderate or Severe), having consumed cocaine within 60 days of application, expressing an intent to reduce or abstain from further consumption of the substance as well as possessing normal vision and hearing abilities - corrected if necessary."
Does this trial offer inclusion to those aged 25 and above?
"This medical trial is currently seeking participants who are aged between 18 and 75."
Are there any available slots left in this research initiative?
"According to the clinicaltrials.gov website, this medical trial is presently searching for participants and has been since it was initially posted on November 13th 2019. The details of the study have also been revised as recently as November 14th 2022."
What objectives is this clinical trial striving to fulfill?
"The 12-week Treatment Interval of this trial primarily aims to assess the Longest Duration of Cocaine Abstinence. Measurable secondary objectives include Total Non-CM Treatment Encounters (Number of non-CM treatment encounters during treatment), % Self-Reported Cocaine Abstinent Days During Treatment (Proportion of self-reported cocaine abstinent days) and % Self Reported Drug and Alcohol Abstinent Days During Treatment (Proportion of self reported drug and alcohol abstainent days)."
Share this study with friends
Copy Link
Messenger